Chardan initiates independent equity research coverage on StemCells

NewsGuard 100/100 Score
Nov 20 2010

StemCells, Inc. (Nasdaq:STEM) announced today that Chardan Capital Markets (Chardan) initiated independent equity research coverage on the Company with a "Buy" recommendation and a 12-month price target of $1.45 per share. The new report, issued yesterday, was authored by Keay Nakae, Senior Analyst at Chardan. 

Chardan is the second firm to initiate independent equity research coverage of StemCells, Inc. this year. Headquartered in New York, Chardan is an investment banking and institutional brokerage firm with a focus on micro, small, and mid-cap markets. More information about Chardan is available at www.chardancm.com. StemCells does not endorse or adopt the reports, projections or statements of any analyst.

Source:

 StemCells, Inc.

Posted in:

Tags: , , , , , ,

Comments (0)

Suggested Reading

Unraveling the complexities of muscle repair in diabetes: A call for targeted research and therapies
Research confirms no association between SARS-CoV-2 and childhood asthma diagnoses
Do you wear makeup while you exercise? New research reveals the effects on skin and pores
Expanding research and clinical options for children with cancer
Research explores the health benefits of resistant starch in plant-based diets
Diet's role in fighting vitiligo highlighted in new research
Rising antibiotic resistance prompts shift to ecological research strategies in infection control
Research finds link between unhealthy eating and chronic pain severity, calls for comprehensive dietary support

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
New research sheds light on how GLP-1 obesity drugs may change food cravings